Activated protein C resistance in hepatic and portal vein thrombosis
Fibrinolysis and Proteolysis, cilt.14, sa.SUPPL. 1, ss.81, 2000 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 14 Sayı: SUPPL. 1
- Basım Tarihi: 2000
- Dergi Adı: Fibrinolysis and Proteolysis
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.81
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
The activated protein C resistance (APC-R) has been shown to be the most frequent cause of hereditary thrombophilia. The association of APCR with Budd-Chiari syndrome (BCS) and portal vein thrombosis (PVT) has not been fully elucidated. In order to investigate this association we studied 23 patients with PVT (ten idiopatic), four patients with BCS, 37 patients with liver cirrhosis and 42 healthy controls. APC-R was detected by the modified method using factor V-deficient plasma. Nine (39%) patients with PVT (four in idiopathic group), three (75%) patients with BCS, eight (21%) patients with liver cirrhosis and five (12%) healthy control subjects were identified as having APC resistance. APC-R was significantly higher in patients with BCS, compared with PVT, liver cirrhosis and controls (P< 0.01). Also APC-R was significantly higher in patients with PVT and liver cirrhosis, compared with control (P < 0.05). There were three patients with a history of deep vein thrombosis and five patients with PVT within the liver cirrhosis group. When these eight patients were excluded, only three (10%) of the remaining 29 liver cirrhosis patients had APC-R and this value was not different from the healthy controls. In conclusion the APC-R is an important factor in the pathogenesis of BCS and PVT and screening for the APC-R must be included in the investigation of patients presenting with this condition.